systemic proteolytic enzyme (Tibrolin)
Phase 3Small molecule
systemic proteolytic enzyme (Tibrolin) is one of 36 small molecule programs targeting Inflammatory Response. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
80 competitors in Inflammatory Response
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Cyklokapron
AAmring
Phase 3
Arcoxia
NovartisPhase 2
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Chirocaine
PPurdue Pharma LP
Phase 2
Ketalar
AAultman Health Foundation
Phase 2
Bayer Aspirin
BayerPhase 1
Tysabri
BiogenPhase 1
systemic proteolytic enzyme (Tibrolin)
UUniversity of Baghdad
Phase 3
Neoral
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Baghdad